Vitamin d brain scans aim to uncover opioid disorder clues

NCT ID NCT06261905

Completed Knowledge-focused Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 study at Yale University looked at how vitamin D (calcitriol) affects dopamine receptors in the brains of people with opioid use disorder. Five participants received either vitamin D or a placebo and had PET scans to measure brain activity. The goal was to understand the brain's dopamine system better, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Calcitriol (active form of vitamin D)
What this could lead to: If successful, this could point toward vitamin D as a potential add-on treatment to help manage opioid use disorder.
What could go wrong: This is a very small early-phase study with only 5 participants, so results may not apply broadly. It is designed to measure brain activity, not to test treatment effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID-USE DISORDER

Contacts and locations

Locations

Yale School of Medicine

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.